Cowen Remains Bullish on XOMA (XOMA) Ahead of EYEGUARD-B Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- NVIDIA (NVDA) Tops Q2 EPS by 14c, Offers Guidance
UPDATE: XOMA (XOMA) Gains in Anticipation of Positive Gevokizumab Data
July 9, 2015 11:32 AM EDT(Updated - July 9, 2015 11:56 AM EDT)
XOMA (NASDAQ: XOMA) shares jumped late Thursday morning as traders positioned in anticipation of Gevokizumab phase III EYEGUARD-B data in Behcets Disease. The data is expected "imminently," said RBC Capital's Adnan Butt in research... More
